Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Abstract The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough. Nevertheless, the utilization and effectiveness of CAR-T cell therapy in solid tumors are still limited primarily because of the a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-04-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-024-03315-3 |
| _version_ | 1827276931932880896 |
|---|---|
| author | Tong Chen Mingzhao Wang Yanchao Chen Yutao Liu |
| author_facet | Tong Chen Mingzhao Wang Yanchao Chen Yutao Liu |
| author_sort | Tong Chen |
| collection | DOAJ |
| description | Abstract The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough. Nevertheless, the utilization and effectiveness of CAR-T cell therapy in solid tumors are still limited primarily because of the absence of tumor-specific target antigen, the existence of immunosuppressive tumor microenvironment, restricted T cell invasion and proliferation, and the occurrence of severe toxicity. This review explored the history of CAR-T and its latest advancements in the management of solid tumors. According to recent studies, optimizing the design of CAR-T cells, implementing logic-gated CAR-T cells and refining the delivery methods of therapeutic agents can all enhance the efficacy of CAR-T cell therapy. Furthermore, combination therapy shows promise as a way to improve the effectiveness of CAR-T cell therapy. At present, numerous clinical trials involving CAR-T cells for solid tumors are actively in progress. In conclusion, CAR-T cell therapy has both potential and challenges when it comes to treating solid tumors. As CAR-T cell therapy continues to evolve, further innovations will be devised to surmount the challenges associated with this treatment modality, ultimately leading to enhanced therapeutic response for patients suffered solid tumors. |
| first_indexed | 2024-04-24T07:12:18Z |
| format | Article |
| id | doaj.art-d77af0400d1449c7933c92789285d31d |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-04-24T07:12:18Z |
| publishDate | 2024-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-d77af0400d1449c7933c92789285d31d2024-04-21T11:31:01ZengBMCCancer Cell International1475-28672024-04-0124112410.1186/s12935-024-03315-3Current challenges and therapeutic advances of CAR-T cell therapy for solid tumorsTong Chen0Mingzhao Wang1Yanchao Chen2Yutao Liu3Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeAbstract The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough. Nevertheless, the utilization and effectiveness of CAR-T cell therapy in solid tumors are still limited primarily because of the absence of tumor-specific target antigen, the existence of immunosuppressive tumor microenvironment, restricted T cell invasion and proliferation, and the occurrence of severe toxicity. This review explored the history of CAR-T and its latest advancements in the management of solid tumors. According to recent studies, optimizing the design of CAR-T cells, implementing logic-gated CAR-T cells and refining the delivery methods of therapeutic agents can all enhance the efficacy of CAR-T cell therapy. Furthermore, combination therapy shows promise as a way to improve the effectiveness of CAR-T cell therapy. At present, numerous clinical trials involving CAR-T cells for solid tumors are actively in progress. In conclusion, CAR-T cell therapy has both potential and challenges when it comes to treating solid tumors. As CAR-T cell therapy continues to evolve, further innovations will be devised to surmount the challenges associated with this treatment modality, ultimately leading to enhanced therapeutic response for patients suffered solid tumors.https://doi.org/10.1186/s12935-024-03315-3CAR T cell therapySolid tumorTumor microenvironmentAntigenHeterogeneityT cell exhaustion |
| spellingShingle | Tong Chen Mingzhao Wang Yanchao Chen Yutao Liu Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors Cancer Cell International CAR T cell therapy Solid tumor Tumor microenvironment Antigen Heterogeneity T cell exhaustion |
| title | Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors |
| title_full | Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors |
| title_fullStr | Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors |
| title_full_unstemmed | Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors |
| title_short | Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors |
| title_sort | current challenges and therapeutic advances of car t cell therapy for solid tumors |
| topic | CAR T cell therapy Solid tumor Tumor microenvironment Antigen Heterogeneity T cell exhaustion |
| url | https://doi.org/10.1186/s12935-024-03315-3 |
| work_keys_str_mv | AT tongchen currentchallengesandtherapeuticadvancesofcartcelltherapyforsolidtumors AT mingzhaowang currentchallengesandtherapeuticadvancesofcartcelltherapyforsolidtumors AT yanchaochen currentchallengesandtherapeuticadvancesofcartcelltherapyforsolidtumors AT yutaoliu currentchallengesandtherapeuticadvancesofcartcelltherapyforsolidtumors |